Roche's Genentech Ups Investment in North Carolina Facility to $2B

Dow Jones01-20

By Elias Schisgall

Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion.

The biotechnology company, a Roche subsidiary, said Tuesday that the expansion of the project in Holly Springs, N.C. would increase the facility's production capacity and output. It will also create an additional 100 jobs, the company said.

"The company decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area," Genentech said Tuesday.

The facility is expected to be operational by 2029 and will produce treatments for metabolic conditions, including obesity. The total project will support more than 500 manufacturing jobs and 1,500 construct jobs, the company said.

The expansion of the Holly Springs facility is part of Roche's pledge to invest $50 billion in U.S. manufacturing and research and development.

"This expansion reflects our long-term commitment to the United States and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible," Genentech Chief Executive Officer Ashley Magargee said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 20, 2026 10:49 ET (15:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604271112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604271112","market":"fut","top_or_hot":-1,"title":"Roche's Genentech Ups Investment in North Carolina Facility to $2B","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion. \n</p>\n<p>\n  The biotechnology company, a Roche subsidiary, said Tuesday that the expansion of the project in Holly Springs, N.C. would increase the facility's production capacity and output. It will also create an additional 100 jobs, the company said. \n</p>\n<p>\n  \"The company decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area,\" Genentech said Tuesday. \n</p>\n<p>\n  The facility is expected to be operational by 2029 and will produce treatments for metabolic conditions, including obesity. The total project will support more than 500 manufacturing jobs and 1,500 construct jobs, the company said. \n</p>\n<p>\n  The expansion of the Holly Springs facility is part of Roche's pledge to invest $50 billion in U.S. manufacturing and research and development. \n</p>\n<p>\n  \"This expansion reflects our long-term commitment to the United States and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible,\" Genentech Chief Executive Officer Ashley Magargee said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2026 10:49 ET (15:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Genentech Ups Investment in North Carolina Facility to $2B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Genentech Ups Investment in North Carolina Facility to $2B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-20 23:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion. \n</p>\n<p>\n  The biotechnology company, a Roche subsidiary, said Tuesday that the expansion of the project in Holly Springs, N.C. would increase the facility's production capacity and output. It will also create an additional 100 jobs, the company said. \n</p>\n<p>\n  \"The company decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area,\" Genentech said Tuesday. \n</p>\n<p>\n  The facility is expected to be operational by 2029 and will produce treatments for metabolic conditions, including obesity. The total project will support more than 500 manufacturing jobs and 1,500 construct jobs, the company said. \n</p>\n<p>\n  The expansion of the Holly Springs facility is part of Roche's pledge to invest $50 billion in U.S. manufacturing and research and development. \n</p>\n<p>\n  \"This expansion reflects our long-term commitment to the United States and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible,\" Genentech Chief Executive Officer Ashley Magargee said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2026 10:49 ET (15:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2604271112","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604271112","pubTimestamp":1768924140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion.The biotechnology company, a Roche subsidiary, said Tuesday that the expansion of the project in Holly Springs, N.C. would increase the facility's production capacity and output. It will also create an additional 100 jobs, the company said.\"The company decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area,\" Genentech said Tuesday.The facility is expected to be operational by 2029 and will produce treatments for metabolic conditions, including obesity. The total project will support more than 500 manufacturing jobs and 1,500 construct jobs, the company said.The expansion of the Holly Springs facility is part of Roche's pledge to invest $50 billion","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RHHBY":"罗氏控股","03165":"华夏欧优股对冲","CARO":"Carolina Financial Corporation"},"translate_title":"罗氏基因泰克将北卡罗来纳州工厂的投资增加至20亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9,"CARO":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Genentech will more than double its investment in a North Carolina manufacturing facility, bringing the total commitment to about $2 billion. \n\n\n  The biotechnology company, a Roche subsidiary, said Tuesday that the expansion of the project in Holly Springs, N.C. would increase the facility's production capacity and output. It will also create an additional 100 jobs, the company said. \n\n\n  \"The company decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area,\" Genentech said Tuesday. \n\n\n  The facility is expected to be operational by 2029 and will produce treatments for metabolic conditions, including obesity. The total project will support more than 500 manufacturing jobs and 1,500 construct jobs, the company said. \n\n\n  The expansion of the Holly Springs facility is part of Roche's pledge to invest $50 billion in U.S. manufacturing and research and development. \n\n\n  \"This expansion reflects our long-term commitment to the United States and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible,\" Genentech Chief Executive Officer Ashley Magargee said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2026 10:49 ET (15:49 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604271112","isCrawlerRequest":true}